Moreover, these observations have immediate implications for cancer immunotherapy approaches, including combination strategies that rely on HPK1 inhibition as a T cell functional augmentation strategy in the context of immune checkpoint therapy resistance. This evidence concerns the gene MAP4K1 and cancer.